[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/DOID_3393",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/DOID_3393"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/drugbank:DB00953"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "\"Rizatriptan benzoate tablets are contraindicated in patients with: * Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease  [see Warnings and Precautions ( 5.1 * Coronary artery vasospasm including Prinzmetal's angina  [see Warnings and Precautions ( 5.1 * History of stroke or transient ischemic attack (TIA)  [see Warnings and Precautions ( 5.4 * Peripheral vascular disease (PVD)  [see Warnings and Precautions ( 5.5 * Ischemic bowel disease  [see Warnings and Precautions ( 5.5 * Uncontrolled hypertension  [see Warnings and Precautions ( 5.8 * Recent use (i.e., within 24 hours) of another 5-HT 1 [see Drug Interactions ( 7.2 7.3 * Hemiplegic or basilar migraine. * Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor  [see Drug Interactions ( 7.5 12.3 * Hypersensitivity to rizatriptan benzoate tablets or rizatriptan benzoate orally disintegrating tablets (angioedema and anaphylaxis seen)  [see Adverse Reactions ( 6.2 * History of ischemic heart disease or coronary artery vasospasm ( 4 * History of stroke or transient ischemic attack ( 4 * Peripheral vascular disease ( 4 * Ischemic bowel disease ( 4 * Uncontrolled hypertension ( 4 * Recent (within 24 hours) use of another 5-HT 1 4 * Hemiplegic or basilar migraine ( 4 * MAO-A inhibitor used in the past 2 weeks ( 4 * Hypersensitivity to rizatriptan benzoate( 4\""
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://schema.org/MedicalContraindication"
    } ]
  }, {
    "@id" : "https://identifiers.org/drugbank:DB00953",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-08-23T18:05:19.392+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "hpr6RALm/XiZ728FefzqvgvfH47zAddRv2y/RB5akx6Io8Bs21nKstq9xcPjflUbDg8KkCdRtsDSbM8ry733FIjrCUtQN5nsY9N5i0B/1HW4PgRADCyPdyvD97FIMhoSFuhCkwvt+1dZ/fUDPGvIAQSh0AbocjYd2iMXgoIksvA="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#pubinfo"
} ]